Systemic treatment for hepatocellular carcinoma

Chronic Diseases and Translational Medicine - Tập 4 - Trang 148-155 - 2018
Manushi Aggarwal1,2, Abeer Arain1,2, Zhaohui Jin1,2
1Carle Cancer Center, Carle Foundation Hospital, 509 W. University Avenue, Urbana, IL 61801, USA
2Department of Internal Medicine, University of Illinois College of Medicine at Urbana-Champaign, Urbana, IL 61801, USA

Tóm tắt

AbstractHepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies.

Tài liệu tham khảo

10.1002/ijc.29210 10.1016/j.jhep.2006.05.013 10.3322/caac.21442 10.1002/cncr.29936 10.1001/jamaoncol.2017.3055 10.3322/caac.20107 10.1016/j.jhep.2011.12.001 10.3322/canjclin.55.2.74 10.1002/hep.24199 10.1002/lt.21999 10.1007/s00261-017-1196-2 10.1055/s-2007-1007122 10.1093/jnci/djn134 10.3390/diseases3040360 10.1159/000481244 10.1159/000343875 10.1016/S1470-2045(17)30683-6 10.1200/JCO.2017.76.0892 10.1016/S0168-8278(18)30424-0 10.1056/NEJMoa0708857 10.1016/S1470-2045(08)70285-7 10.1016/S0140-6736(18)30207-1 10.1016/S0140-6736(16)32453-9 10.1016/j.jhep.2018.04.010 10.1016/S0140-6736(17)31046-2 10.1093/annonc/mdw651 10.1200/JCO.2018.36.4_suppl.207 10.1056/NEJMoa1717002 10.1200/JCO.2018.36.15_suppl.4019 10.1080/13102818.2014.981776 10.1200/JCO.2018.36.4_suppl.TPS538 Zhu A.X., 2018, REACH‐2: A randomized, double‐blind, placebo‐controlled phase 3 study of ramucirumab versus placebo as second‐line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha‐fetoprotein (AFP) following first‐line sorafenib, J Clin Oncol, 36, 4003, 10.1200/JCO.2018.36.15_suppl.4003 10.1200/JCO.2012.45.8372 10.1200/JCO.2012.48.4410 10.1200/JCO.2013.54.3298 10.1016/S1470-2045(15)00050-9 10.1001/jama.2014.7189 10.1016/S1470-2045(18)30146-3 10.1200/JCO.2018.36.4_suppl.209 10.1200/JCO.2017.35.4_suppl.TPS503 10.1200/JCO.2018.36.15_suppl.TPS3110 10.1056/NEJMoa1712126 10.1056/NEJMoa1504030 10.1200/JCO.2018.36.15_suppl.TPS4144 10.1200/JCO.2018.36.15_suppl.4075 10.2147/JHC.S122507 10.1200/JCO.2018.36.15_suppl.TPS3135 10.1200/JCO.2018.36.15_suppl.2509
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 4

148-155

Thông tin tác giả